Tau-positron emission tomography correlates with neuropathology findings.

Lowe, Val J.; Lundt, Emily S.; Albertson, Sabrina M.; Min, Hoon‐Ki; Fang, Ping; Przybelski, Scott A.; Senjem, Matthew L.; Schwarz, Christopher G.; Kantarci, Kejal; Boeve, Bradley; Jones, David T.; Reichard, R. Ross; Tranovich, Jessica F.; Hanna Al‐Shaikh, Fadi S.; Knopman, David S.; Jack, Clifford R.; Dickson, Dennis W.; Petersen, Ronald C.; Murray, Melissa E.

doi:10.1016/j.jalz.2019.09.079

Cited by 203Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

Tau-positron emission tomography correlates with neuropathology findings.

Open access

Lowe, Val J., Lundt, Emily S., Albertson, Sabrina M., Min, Hoon‐Ki, Fang, Ping, Przybelski, Scott A., Senjem, Matthew L., Schwarz, Christopher G. +11 more·2020·Alzheimer's & Dementia

DOI 10.1016/j.jalz.2019.09.079PMC PMC7067654

Open this paper in CoChat — free account

Abstract

INTRODUCTION: Comparison of tau (flortaucipir) positron emission tomography (FTP-PET) to autopsy is important to demonstrate the relationship of FTP-PET to neuropathologic findings. METHODS: Autopsies were performed on 26 participants who had antemortem FTP-PET. FTP-PET standardized uptake value ratios (SUVRs) were compared to autopsy diagnoses and Braak tangle stage. Quantitative tau burden was compared to regional FTP-PET signal. RESULTS: Participants with Braak stages of IV or greater had elevated FTP-PET signal. FTP-PET was elevated in participants with Alzheimer's disease. An FTP-PET SUVR cut point of 1.29 was determined to be optimal. Quantitative measurements of hippocampal and temporal lobe tau burden were highly correlated to FTP-PET signal (rho's from 0.61 to 0.70, P ≤ .02). DISCUSSION: Elevated FTP-PET reflects Braak IV or greater neuropathology. Participants with primary age-related tauopathy and hippocampal sclerosis did not show elevated FTP-PET signal. Secondary neuropathologic diagnoses of Alzheimer's disease neuropathologic change can lead to borderline elevated FTP-PET signal.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2019.09.079

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Studies combining antemortem imaging with neuropathological validation have shown 18F-flortaucipir PET is highly sensitive for presence of high levels of AD neuropathological change, with visual rating positivity corresponding to Braak levels IV or greater.
“Studies combining antemortem imaging with neuropathological validation have shown that 18F-flortaucipir PET is highly sensitive for presence of high levels of AD neuropathological change with visual rating positivity corresponding to Braak levels IV or greater [184, 185].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [185]
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
Studies comparing antemortem tau positron emission tomography imaging with autopsy have begun assessing the ability of flortaucipir to detect underlying neurofibrillary tangles in Alzheimer disease and non-Alzheimer disease dementias.
“Studies comparing antemortem tau PET imaging with autopsy have begun assessing the ability of flortaucipir to detect underlying NFTs in AD and non-AD dementias.25,26,27,28,29,30,31,32,33”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [25]
A recent study of 26 cases comparing flortaucipir PET image and autopsy findings demonstrated sensitivity 87% and specificity 82% for identifying AD-spectrum pathological diagnoses, using quantitative analysis of a mesial, inferior, or middle temporal lobe region of interest.
“In support of this finding and the quantitative data presented herein, a recent study of 26 cases comparing flortaucipir PET image and autopsy findings demonstrated a sensitivity of 87% and specificity of 82% for identifying AD-spectrum pathological diagnoses, using quantitative analysis of a mesial, inferior, or middle temporal lobe region of interest.25”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [25]
Twelve of these autopsy-confirmed cases had pathological evidence of Braak stages IV to VI NFTs (2 cases with Braak stage IV) with moderate to frequent neuritic plaques and were above the SUVR threshold for positivity for the flortaucipir temporal lobe region of interest.
“Twelve of these autopsy-confirmed cases had pathological evidence of Braak stages IV to VI NFTs (2 cases with Braak stage IV) with moderate to frequent neuritic plaques and were above the SUVR threshold for positivity for the [18F]flortaucipir temporal lobe region of interest.”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [25]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697 · see citing works
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961 · see citing works
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476 · see citing works
Self-citation
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · see citing works
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · see citing works
Self-citation
National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,992 · cited 1× · see citing works
“Mean (SD) 18 (8) 29 24 27 (2) 22 (6) 28 (1) 26 (4) 21 22 (7) GMWMPVCNPiB SUVR†”
Self-citation
Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · see citing works
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467 · see citing works
Self-citation
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931 · see citing works
Self-citation
Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy)
Hauw, J., Daniel, S. E., Dickson, D. W., Horoupian, D. S., Jellinger, K. A., Lantos, P. L., McKee, A. C., Tabaton, M., & Litvan, I. (1994) · Neurology · doi:10.1212/wnl.44.11.2015 · Cited by 854 · see citing works
Self-citation
Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724 · see citing works
Self-citation
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808
Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C. A., Shankle, W. R., Lerner, A. J., Su, M., Elizarov, A. M., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130098 · Cited by 676 · see citing works
Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651 · see citing works
Validating novel tau positron emission tomography tracer <scp>[F‐18]‐AV‐1451 (T807)</scp> on postmortem brain tissue
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615 · see citing works
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · see citing works
Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function
Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L., & Arnold, S. E. (2004) · Archives of Neurology · doi:10.1001/archneur.61.3.378 · Cited by 526 · see citing works
Consortium to Establish a Registry for Alzheimer's Disease (CERAD): The first twenty years
Fillenbaum, G. G., van Belle, G., Morris, J. C., Mohs, R. C., Mirra, S. S., Davis, P. C., Tariot, P. N., Silverman, J. M., Clark, C. M., Welsh-Bohmer, K. A., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.08.005 · Cited by 477 · see citing works
An autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474 · see citing works
Self-citation
Longitudinal tau PET in ageing and Alzheimer’s disease
Jack, C. R., Wiste, H. J., Schwarz, C. G., Lowe, V. J., Senjem, M. L., Vemuri, P., Weigand, S. D., Therneau, T. M., Knopman, D. S., Gunter, J. L., et al. (2018) · Brain · doi:10.1093/brain/awy059 · Cited by 452 · see citing works
Self-citation
Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations
Mackenzie, I. R., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I. I., Kril, J. J., Kovács, G. G., Ghetti, B. F., Halliday, G. M., Holm, I. E., et al. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0460-5 · Cited by 418 · see citing works
Self-citation
Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree--a new disease?
Kosaka, K., Yoshimura, M., Ikeda, K., & Budka, H. (1984) · PubMed · Cited by 401 · see citing works
Widespread brain tau and its association with ageing, Braak stage and Alzheimer’s dementia
Lowe, V. J., Wiste, H. J., Senjem, M. L., Weigand, S. D., Therneau, T. M., Boeve, B. F., Josephs, K. A., Fang, P., Pandey, M. K., Murray, M. E., et al. (2017) · Brain · doi:10.1093/brain/awx320 · Cited by 302 · see citing works
Self-citation
The Youden Index and the Optimal Cut‐Point Corrected for Measurement Error
Perkins, N. J., & Schisterman, E. F. (2005) · Biometrical Journal · doi:10.1002/bimj.200410133 · Cited by 289 · see citing works
Comparative evaluation of MR-based partial-volume correction schemes for PET.
MELTZER, C. C., Kinahan, P. E., Greer, P. J., Nichols, T. E., Comtat, C., Cantwell, M. N., Lin, M., & Price, J. C. (1999) · PubMed · Cited by 254 · see citing works
Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias
Murray, M. E., Kouri, N., Lin, W.-L., Jack, C. R., Dickson, D. W., & Vemuri, P. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt231 · Cited by 237 · see citing works
Self-citation
Globular glial tauopathies (GGT): consensus recommendations
Ahmed, Z., Bigio, E. H., Budka, H., Dickson, D. W., Ferrer, I., Ghetti, B. F., Giaccone, G., Hatanpaa, K. J., Holton, J. L., Josephs, K. A., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1171-0 · Cited by 205 · see citing works
Self-citation
Pathological correlations of [F‐18]‐AV‐1451 imaging in non‐alzheimer tauopathies
Marquié, M., Normandin, M. D., Meltzer, A. C., Siao Tick Chong, M., Andrea, N. V., Antón‐Fernández, A., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24844 · Cited by 190 · see citing works
Multimodality imaging characteristics of dementia with Lewy bodies
Kantarci, K., Lowe, V. J., Boeve, B. F., Weigand, S. D., Senjem, M. L., Przybelski, S. A., Dickson, D. W., Parisi, J. E., Knopman, D. S., Smith, G. E., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.024 · Cited by 175 · see citing works
Self-citation
Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease
Harada, R., Ishiki, A., Kai, H., Sato, N., Furukawa, K., Furumoto, S., Tago, T., Tomita, N., Watanuki, S., Hiraoka, K., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.197426 · Cited by 168 · see citing works
Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology
Hashimoto, H., Kawamura, K., Igarashi, N., Takei, M., Fujishiro, T., Aihara, Y., Shiomi, S., Muto, M., Ito, T., Furutsuka, K., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.139550 · Cited by 151 · see citing works
Differential clinicopathologic and Genetic features of late-onset amnestic dementias
Murray, M., Cannon, A., Graff-Radford, N., Liesinger, A. M., Rutherford, N., Ross, O., Duara, R., Carrasquillo, M., Rademakers, R., & Dickson, D. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1302-2 · Cited by 150 · see citing works
Self-citation
Modeling the Relation Between Neurofibrillary Tangles and Intellectual Status
Duyckaerts, C. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)80306-5 · Cited by 150 · see citing works
Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case.
Marquié, M., Verwer, E. E., Meltzer, A. C., Kim, S. J. W., Agüero, C., Gonzalez, J., Makaretz, S. J., Siao Tick Chong, M., Ramanan, P., Amaral, A. C., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0482-0 · Cited by 128 · see citing works
[18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration.
Josephs, K. A., Whitwell, J. L., Tacik, P., Duffy, J. R., Senjem, M. L., Tosakulwong, N., Jack, C. R., Lowe, V., Dickson, D. W., & Murray, M. E. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1618-1 · Cited by 127 · see citing works
Self-citation
Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology
Smith, R., Wibom, M., Pawlik, D., Englund, E., & Hansson, O. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3692 · Cited by 111 · see citing works
High Affinity Radiopharmaceuticals Based Upon Lansoprazole for PET Imaging of Aggregated Tau in Alzheimer’s Disease and Progressive Supranuclear Palsy: Synthesis, Preclinical Evaluation, and Lead Selection
Fawaz, M. V., Brooks, A. F., Rodnick, M. E., Carpenter, G. M., Shao, X., Desmond, T. J., Sherman, P. S., Quesada, C., Hockley, B. G., Kilbourn, M. R., et al. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500103u · Cited by 87 · see citing works
Functional, Global and Cognitive Decline Correlates to Accumulation of Alzheimers Pathology in MCI and AD
Sabbagh, M. N., Cooper, K., DeLange, J., Stoehr, J. D., Thind, K., Lahti, T., Reisberg, B., Sue, L., Vedders, L., Fleming, S. R., et al. (2010) · Current Alzheimer Research · doi:10.2174/156720510791162340 · Cited by 79 · see citing works
Developments in Tau PET Imaging
Zimmer, E. R., Leuzy, A., Gauthier, S., & Rosa-Neto, P. (2014) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2014.15 · Cited by 60 · see citing works
Comparison of [18F]Flutemetamol and [11C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals
Lowe, V. J., Lundt, E., Knopman, D., Senjem, M. L., Gunter, J. L., Schwarz, C. G., Kemp, B. J., Jack, C. R., & Petersen, R. C. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.08.011 · Cited by 45 · see citing works
Self-citation
Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer’s disease?
Murray, M., & Dickson, D. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt254 · Cited by 39 · see citing works
Self-citation
In vivo [ 18 F]-AV-1451 tau-PET imaging in sporadic Creutzfeldt-Jakob disease
Day, G. S., Gordon, B. A., Perrin, R. J., Cairns, N. J., Beaumont, H., Schwetye, K., Ferguson, C., Sinha, N., Bucelli, R., Musiek, E. S., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005064 · Cited by 26 · see citing works
An MRI‐Based Atlas for Correlation of Imaging and Pathologic Findings in Alzheimer's Disease
Raman, M. R., Schwarz, C. G., Murray, M. E., Lowe, V. J., Dickson, D. W., Jack, C. R., & Kantarci, K. (2016) · Journal of Neuroimaging · doi:10.1111/jon.12341 · Cited by 4 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803 · see citing works
Self-citation
Four distinct trajectories of tau deposition identified in Alzheimer’s disease
Initiative, T. A. D. N., Vogel, J. W., Young, A. L., Oxtoby, N. P., Smith, R., Ossenkoppele, R., Strandberg, O. T., La Joie, R., Aksman, L. M., Grothe, M. J., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01309-6 · Cited by 741 · see citing works
Performance of plasma phosphorylated tau 181 and 217 in the community
Mielke, M. M., Dage, J. L., Frank, R. D., Algeciras-Schimnich, A., Knopman, D. S., Lowe, V. J., Bu, G., Vemuri, P., Graff-Radford, J., Jack, C. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01822-2 · Cited by 465 · see citing works
Self-citation
Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes
Fleisher, A. S., Pontecorvo, M. J., Devous, M. D., Lu, M., Arora, A. K., Truocchio, S. P., Aldea, P., Flitter, M., Locascio, T., Devine, M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0528 · Cited by 448 · see citing works
Self-citation
Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research
Moloney, C. M., Lowe, V. J., & Murray, M. E. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12321 · Cited by 337 · see citing works
Self-citation
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H. J., Cummings, J. L., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 331 · see citing works
Self-citation
Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging
Ossenkoppele, R., Smith, R., Mattsson-Carlgren, N., Groot, C., Leuzy, A., Strandberg, O., Palmqvist, S., Olsson, T., Jögi, J., Stormrud, E., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.1858 · Cited by 311 · see citing works
18F-MK-6240 PET for early and late detection of neurofibrillary tangles
Pascoal, T. A., Therriault, J., Benedet, A. L., Savard, M., Lussier, F. Z., Chamoun, M., Tissot, C., Qureshi, M. N. I., Kang, M. S., Mathotaarachchi, S. S., et al. (2020) · Brain · doi:10.1093/brain/awaa180 · Cited by 257 · see citing works
CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Horie, K., Salvadó, G., Barthélemy, N. R., Janelidze, S., Li, Y., He, Y., Saef, B., Chen, C. D., Jiang, H., Strandberg, O., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02443-z · Cited by 249 · see citing works
Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes
Mielke, M. M., Frank, R. D., Dage, J. L., Jeromin, A., Ashton, N. J., Blennow, K., Karikari, T. K., Vanmechelen, E., Zetterberg, H., Algeciras-Schimnich, A., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.2293 · Cited by 244 · see citing works
Self-citation
Imaging biomarkers in neurodegeneration: current and future practices
Young, P. N. E., Estarellas, M., Coomans, E. M., Srikrishna, M., Beaumont, H., Maaß, A., Venkataraman, A. V., Lissaman, R., Jiménez, D., Betts, M. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00612-7 · Cited by 229 · see citing works
Microglial activation and tau burden predict cognitive decline in Alzheimer’s disease
Malpetti, M., Kievit, R. A., Passamonti, L., Jones, P. S., Tsvetanov, K. A., Rittman, T., Mak, E., Nicastro, N., Bevan-Jones, W. R., Su, L., et al. (2020) · Brain · doi:10.1093/brain/awaa088 · Cited by 194 · see citing works
The use of neuroimaging techniques in the early and differential diagnosis of dementia
Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 186 · see citing works
“Studies combining antemortem imaging with neuropathological validation have shown that 18 F-ﬂ ortaucipir PET is highly sensitive for presence of high levels of AD neuropathological change with visual rating positivity corresponding to Braak levels IV or greater [184, 185].”
18F-flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases
Soleimani‐Meigooni, D. N., Iaccarino, L., Joie, R. L., Baker, S. L., Bourakova, V., Boxer, A. L., Edwards, L., Eser, R. A., Gorno‐Tempini, M., Jagust, W. J., et al. (2020) · Brain · doi:10.1093/brain/awaa276 · Cited by 178 · see citing works
Dissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R., & Yokoyama, J. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01531-9 · Cited by 151 · see citing works
Predicting amyloid PET and tau PET stages with plasma biomarkers
Jack, C. R., Wiste, H. J., Algeciras‐Schimnich, A., Figdore, D. J., Schwarz, C. G., Lowe, V. J., Ramanan, V. K., Vemuri, P., Mielke, M. M., Knopman, D. S., et al. (2023) · Brain · doi:10.1093/brain/awad042 · Cited by 149 · see citing works
Self-citation
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14338 · Cited by 151 · see citing works
Self-citation
Tau PET Imaging in Neurodegenerative Disorders
Groot, C., Villeneuve, S., Smith, R., Hansson, O., & Ossenkoppele, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263196 · Cited by 137 · see citing works
Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
Ossenkoppele, R., Reimand, J., Smith, R. A., Leuzy, A., Strandberg, O. T., Palmqvist, S., Stomrud, E., Zetterberg, H., Initiative, T. A. D. N., Scheltens, P., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114398 · Cited by 126 · see citing works
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
Horie, K., Salvadó, G., Koppisetti, R. K., Janelidze, S., Barthélemy, N. R., He, Y., Sato, C., Gordon, B. A., Jiang, H., Benzinger, T. L. S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03617-7 · Cited by 131 · see citing works
Dementia with Lewy bodies: Impact of co‐pathologies and implications for clinical trial design
Toledo, J. B., Ruiz, C. A., Weil, R. S., Ferreira, D., Rodriguez‐Porcel, F. E., Pilotto, A., Wyman‐Chick, K. A., Grothe, M. J., Kane, J. P. M., Taylor, A., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12814 · Cited by 109 · see citing works
Self-citation
Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials
Ossenkoppele, R., Salvadó, G., Janelidze, S., Binette, A. P., Bali, D., Karlsson, L., Palmqvist, S., Mattsson, N., Stomrud, E., Therriault, J., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00835-z · Cited by 102 · see citing works
Self-citation
Synergistic association of Aβ and tau pathology with cortical neurophysiology and cognitive decline in asymptomatic older adults
Gallego-Rudolf, J., Wiesman, A. I., Binette, A. P., Villeneuve, S., & Baillet, S. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01763-8 · Cited by 90 · see citing works
Evaluation of [18F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies
Tezuka, T., Takahata, K., Seki, M., Tabuchi, H., Momota, Y., Shiraiwa, M., Suzuki, N., Morimoto, A., Nakahara, T., Iwabuchi, Y., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab190 · Cited by 85 · see citing works
Relevance of biomarkers across different neurodegenerative diseases
Ehrenberg, A. J., Khatun, A., Coomans, E. M., Betts, M. J., Capraro, F., Thijssen, E. H., Senkevich, K. A., Bharucha, T., Jafarpour, M., Young, P. N. E., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00601-w · Cited by 79 · see citing works
Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe
Iaccarino, L., Burnham, S. C., Dell’Agnello, G., Dowsett, S. A., & Epelbaum, S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.43 · Cited by 81 · see citing works
Current directions in tau research: Highlights from Tau 2020
Sexton, C. E., Snyder, H. M., Beher, D., Boxer, A. L., Brannelly, P., Brion, J., Buée, L., Cacace, A. M., Chételat, G., Citron, M., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12452 · Cited by 78 · see citing works
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 82 · see citing works
Self-citation
Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology
Peet, B. T., Spina, S., Mundada, N., & La Joie, R. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01101-x · Cited by 74 · see citing works
Phosphorylated tau sites that are elevated in Alzheimer's disease fluid biomarkers are visualized in early neurofibrillary tangle maturity levels in the post mortem brain
Moloney, C. M., Labuzan, S. A., Crook, J. E., Siddiqui, H., Castanedes‐Casey, M., Lachner, C., Petersen, R. C., Duara, R., Graff‐Radford, N. R., Dickson, D. W., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12749 · Cited by 74 · see citing works
Self-citation
A multilevel view of the development of Alzheimer's Disease.
Ávila, J., & Perry, G. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.11.015 · Cited by 62 · see citing works
Identifying degenerative effects of repetitive head trauma with neuroimaging: a clinically-oriented review
Asken, B. M., & Rabinovici, G. D. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01197-4 · Cited by 68 · see citing works
Plasma biomarkers for Alzheimer’s disease: a field-test in a memory clinic
Altomare, D., Stampacchia, S., Ribaldi, F., Tomczyk, S., Chevalier, C., Poulain, G., Asadi, S., Bancila, B., Marizzoni, M., Martins, M., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-330619 · Cited by 63 · see citing works
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62 · see citing works
International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease
Tian, M., Civelek, A. C., Carrió, I., Watanabe, Y., Kang, K. W., Murakami, K., Garibotto, V., Prior, J. O., Barthel, H., Zhou, R., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05673-w · Cited by 60 · see citing works
Sensitivity–Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration
Ghirelli, A., Tosakulwong, N., Weigand, S. D., Clark, H. M., Ali, F., Botha, H., Duffy, J. R., Utianski, R. L., Buciuc, M., Murray, M. E., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25893 · Cited by 59 · see citing works
Self-citation
Head-to-head comparison of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases
Aguero, C., Dhaynaut, M., Amaral, A., Moon, S.-H., Neelamegam, R., Scapellato, M., Carazo-Casas, C., Kumar, S., Fakhri, G. E., Johnson, K. A., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02672-z · Cited by 54 · see citing works
Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults
Chen, X., Cassady, K. E., Adams, J. N., Harrison, T. M., Baker, S. L., & Jagust, W. J. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.2111-20.2020 · Cited by 59 · see citing works
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels
Murray, M. E., Moloney, C. M., Kouri, N., Syrjanen, J. A., Matchett, B. J., Rothberg, D. M., Tranovich, J. F., Sirmans, T. N. H., Wiste, H. J., Boon, B. D. C., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00578-0 · Cited by 58 · see citing works
Self-citation
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex
Ossenkoppele, R., Coomans, E. M., Apostolova, L. G., Baker, S. L., Barthel, H., Beach, T. G., Benzinger, T. L. S., Betthauser, T. J., Bischof, G. N., Bottlaender, M., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02000-6 · Cited by 56 · see citing works
Self-citation
Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
Bischof, G. N., Dodich, A., Boccardi, M., van Eimeren, T., Festari, C., Barthel, H., Hansson, O., Nordberg, A. K., Ossenkoppele, R., Sabri, O., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05156-4 · Cited by 53 · see citing works
Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease
Trelle, A. N., Carr, V. A., Wilson, E. N., Swarovski, M. S., Hunt, M. P., Toueg, T. N., Tran, T., Channappa, D., Corso, N. K., Thieu, M. K., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011477 · Cited by 52 · see citing works
Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
Groot, C., Smith, R. A., Stomrud, E., Binette, A. P., Leuzy, A., Wuestefeld, A., Wisse, L. E. M., Palmqvist, S., Mattsson, N., Janelidze, S., et al. (2022) · Brain · doi:10.1093/brain/awac329 · Cited by 50 · see citing works
CSF biomarkers and plasma p‐tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design
Moscoso, A., Karikari, T. K., Grothe, M. J., Ashton, N. J., Lantero‐Rodriguez, J., Snellman, A., Zetterberg, H., Blennow, K., & Schöll, M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12570 · Cited by 50 · see citing works
Abnormal tau in amyloid PET negative individuals
Yoon, B., Guo, T., Provost, K., Korman, D., Ward, T. J., Landau, S. M., & Jagust, W. J. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.09.019 · Cited by 48 · see citing works
Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity
Costoya‐Sánchez, A., Moscoso, A., Silva‐Rodríguez, J., Pontecorvo, M. J., Devous, M. D., Aguiar, P., Schöll, M., Grothe, M. J., Initiative, A. D. N., Weiner, M. W., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.2560 · Cited by 48 · see citing works
Self-citation
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
Wolters, E. E., Dodich, A., Boccardi, M., Corre, J., Drzezga, A. E., Hansson, O., Nordberg, A. K., Frisoni, G. B., Garibotto, V., & Ossenkoppele, R. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05118-w · Cited by 47 · see citing works
What’s the cut-point?: a systematic investigation of tau PET thresholding methods
Weigand, A. J., Maaß, A., Eglit, G. L., & Bondi, M. W. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00986-w · Cited by 44 · see citing works
Neuropathology of the Alzheimer's continuum: an update
Jellinger, K. A. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3050 · Cited by 45 · see citing works
Diagnostic biomarkers in Alzheimer’s disease
Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2021.100041 · Cited by 42 · see citing works
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 47 · see citing works
Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET
Cogswell, P. M., Lundt, E. S., Therneau, T. M., Wiste, H. J., Graff‐Radford, J., Algeciras‐Schimnich, A., Lowe, V. J., Mielke, M. M., Schwarz, C. G., Senjem, M. L., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13539 · Cited by 37 · see citing works
Self-citation
Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison
Altomare, D., Caprioglio, C., Assal, F., Allali, G., Mendes, A., Ribaldi, F., Ceyzériat, K., Martins, M., Tomczyk, S., Stampacchia, S., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05246-x · Cited by 40 · see citing works
Relationships between β-amyloid and tau in an elderly population: An accelerated failure time model
Therneau, T. M., Knopman, D. S., Lowe, V. J., Botha, H., Graff‐Radford, J., Jones, D. T., Vemuri, P., Mielke, M. M., Schwarz, C. G., Senjem, M. L., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118440 · Cited by 36 · see citing works
Self-citation
A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation
Giorgio, J., Jagust, W. J., Baker, S. L., Landau, S. M., Peter Tiňo, B., Kourtzi, Z., & Initiative, A. D. N. (2022) · Nature Communications · doi:10.1038/s41467-022-28795-7 · Cited by 40 · see citing works
Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome
Corriveau‐Lecavalier, N., Botha, H., Graff‐Radford, J., Switzer, A. R., Przybelski, S. A., Wiste, H. J., Murray, M. E., Reichard, R. R., Dickson, D. W., Nguyen, A. T., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae183 · Cited by 39 · see citing works
Self-citation
[ 18 F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers
Wolters, E. E., Papma, J. M., Verfaillie, S. C. J., Visser, D., Weltings, E., Groot, C., van der Ende, E. L., Giannini, L. A. A., Tuncel, H., Timmers, T., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012448 · Cited by 38 · see citing works
Early neuroinflammation is associated with lower amyloid and tau levels in cognitively normal older adults
Albrecht, D. S., Sagare, A., Pachicano, M., Sweeney, M. D., Toga, A., Zlokovic, B., Chui, H., Joe, E., Schneider, L., Morris, J. C., et al. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.01.010 · Cited by 37 · see citing works
Flortaucipir PET uncovers relationships between tau and amyloid-β in primary age–related tauopathy and Alzheimer’s disease
Josephs, K. A., Tosakulwong, N., Weigand, S. D., Graff‐Radford, J., Schwarz, C. G., Senjem, M. L., Machulda, M. M., Kantarci, K., Knopman, D. S., Nguyen, A. T., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado8076 · Cited by 35 · see citing works
Self-citation
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
Rubinski, A., Franzmeier, N., Dewenter, A., Luan, Y., Smith, R. A., Strandberg, O. T., Ossenkoppele, R., Dichgans, M., Hansson, O., Ewers, M., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01074-9 · Cited by 38 · see citing works
P-tau217 in Alzheimer’s disease
Telser, J., Risch, L., Saely, C. H., Grossmann, K., & Werner, P. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.03.018 · Cited by 33 · see citing works
Evaluation of [ 18 F]-JNJ-64326067-AAA tau PET tracer in humans
Baker, S. L., Provost, K., Thomas, W., Whitman, A., Janabi, M., Schmidt, M. E., Timmers, M., Kolb, H. C., Rabinovici, G. D., & Jagust, W. J. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x211031035 · Cited by 32 · see citing works
Rates of longitudinal change in 18F‐flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease
Phillips, J. S., Nitchie, F. J., Re, F. D., Olm, C. A., Cook, P. A., McMillan, C. T., Irwin, D. J., Gee, J. C., Dubroff, J. G., Grossman, M., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12456 · Cited by 31 · see citing works
Association of in vivo retention of [18f] flortaucipir pet with tau neuropathology in corresponding brain regions
Freiburghaus, T., Pawlik, D., Hauer, K. O., Ossenkoppele, R., Strandberg, O. T., Leuzy, A., Rittmo, J. Ö., Tremblay, C., Serrano, G. E., Pontecorvo, M. J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02801-2 · Cited by 30 · see citing works
Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case–control study
Boon, B. D. C., Piura, Y. D., Moloney, C. M., Chalk, J. L., Lincoln, S., Rutledge, M. H., Rothberg, D. M., Kouri, N., Hinkle, K. M., Roemer, S. F., et al. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00313-8 · Cited by 34 · see citing works
Self-citation
Imaging tau burden in dementia with Lewy bodies using [18F]-AV1451 positron emission tomography
Mak, E., Nicastro, N., Malpetti, M., Savulich, G., Surendranathan, A., Holland, N., Passamonti, L., Jones, P. S., Carter, S. F., Su, L., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.11.006 · Cited by 30 · see citing works
White Matter Degeneration Pathways Associated With Tau Deposition in Alzheimer Disease
Tian, J., Raghavan, S., Reid, R. I., Przybelski, S. A., Lesnick, T. G., Gebre, R. K., Graff-Radford, J., Schwarz, C. G., Lowe, V. J., Kantarci, K., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207250 · Cited by 29 · see citing works
Self-citation
Synthesizing images of tau pathology from cross-modal neuroimaging using deep learning
Lee, J., Burkett, B. J., Min, H.-K. P., Senjem, M. L., Dicks, E., Corriveau‐Lecavalier, N., Mester, C. T., Wiste, H. J., Lundt, E. S., Murray, M. E., et al. (2023) · Brain · doi:10.1093/brain/awad346 · Cited by 28 · see citing works
Self-citation
A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles
Burnham, S. C., Iaccarino, L., Pontecorvo, M. J., Fleisher, A., Lu, M., Collins, E. C., & Devous, M. D. (2023) · Brain Communications · doi:10.1093/braincomms/fcad305 · Cited by 29 · see citing works
Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W
Qi, C., Lövestam, S., Murzin, A. G., Peak‐Chew, S., Franco, C. D. M. F., Bogdani, M., Latimer, C. S., Murrell, J. R., Cullinane, P. W., Jaunmuktane, Z., et al. (2025) · Nature Structural & Molecular Biology · doi:10.1038/s41594-025-01498-5 · Cited by 27 · see citing works
Development, initial validation, and application of a visual read method for [ 18 F]MK‐6240 tau PET
Shuping, J., Matthews, D. C., Adamczuk, K., Scott, D., Rowe, C. C., Kreisl, W. C., Johnson, S. C., Lukic, A. S., Johnson, K. A., Rosa‐Neto, P., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12372 · Cited by 26 · see citing works
Regional Tau Deposition Reflects Different Pathways of Subsequent Neurodegeneration and Memory Decline in Cognitively Normal Older Adults
Chen, X., Toueg, T. N., Harrison, T. M., Baker, S. L., & Jagust, W. J. (2023) · Annals of Neurology · doi:10.1002/ana.26813 · Cited by 25 · see citing works
Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years
Josephs, K. A., Weigand, S. D., & Whitwell, J. L. (2022) · Neurology · doi:10.1212/wnl.0000000000200287 · Cited by 38 · see citing works
Evaluation of Neurodegenerative Disorders with Amyloid-β, Tau, and Dopaminergic PET Imaging: Interpretation Pitfalls
Burkett, B. J., Johnson, D. R., & Lowe, V. J. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.266463 · Cited by 25 · see citing works
Self-citation
Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression
Kotari, V., Southekal, S. S., Navitsky, M. A., Kennedy, I. A., Lu, M., Morris, A., Zimmer, J. A., Fleisher, A., Mintun, M. A., Devous, M. D., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01160-6 · Cited by 23 · see citing works
Multimodal in vivo and postmortem assessments of tau in Lewy body disorders
Coughlin, D. G., Phillips, J. S., Roll, E. E., Peterson, C. S., Lobrovich, R., Rascovsky, K., Ungrady, M. B., Wolk, D. A., Das, S. R., Weintraub, D. A., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.08.003 · Cited by 23 · see citing works
The many faces of globular glial tauopathy: A clinical and imaging study
Buciuc, M., Koga, S., Pham, N. T. T., Duffy, J. R., Knopman, D. S., Ali, F., Boeve, B. F., Graff‐Radford, J., Botha, H., Lowe, V. J., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15603 · Cited by 23 · see citing works
Self-citation
Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies
Chen, Q., Przybelski, S. A., Senjem, M. L., Schwarz, C. G., Lesnick, T. G., Botha, H., Knopman, D. S., Graff‐Radford, J., Savica, R., Jones, D. T., et al. (2022) · Movement Disorders · doi:10.1002/mds.28973 · Cited by 23 · see citing works
Self-citation
MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous
Josephs, K. A., Tosakulwong, N., Graff‐Radford, J., Weigand, S. D., Buciuc, M., Machulda, M. M., Jones, D. T., Schwarz, C. G., Senjem, M. L., Ertekin‐Taner, N., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51038 · Cited by 22 · see citing works
Self-citation
1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults
Kara, F., Joers, J. M., Deelchand, D. K., Park, Y. W., Przybelski, S. A., Lesnick, T. G., Senjem, M. L., Zeydan, B., Knopman, D. S., Lowe, V. J., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.12.010 · Cited by 22 · see citing works
Self-citation
Current and Future Trends in Biomarkers for the Early Detection of Alzheimer’s Disease in Asia: Expert Opinion
Kandiah, N., Choi, S. H., Hu, C., Ishii, K., Kasuga, K., & Mok, V. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-220059 · Cited by 23 · see citing works
In Vivo 18F-Flortaucipir PET Does Not Accurately Support the Staging of Progressive Supranuclear Palsy
Malpetti, M., Kaalund, S. S., Tsvetanov, K. A., Rittman, T., Briggs, M., Allinson, K. S. J., Passamonti, L., Holland, N., Jones, P. S., Fryer, T. D., et al. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262985 · Cited by 21 · see citing works
Tau burden is best captured by magnitude and extent: Tau‐MaX as a measure of global tau
Brown, C., Das, S. R., Cousins, K. A. Q., Tropea, T. F., Plotkin, A., Detre, J. A., Yushkevich, P. A., McMillan, C. T., Lee, E. B., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70346 · Cited by 20 · see citing works
ACR Appropriateness Criteria® Dementia: 2024 Update
Soderlund, K. A., Austin, M. J., Ben‐Haim, S., Chu, S., Ivanidze, J., Joshi, P., Kalnins, A., Kennedy, M., Kulshreshtha, A., Kuo, P. H., et al. (2025) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2025.02.031 · Cited by 22 · see citing works
Preclinical Characterization of the Tau PET Tracer [18F]SNFT-1: Comparison of Tau PET Tracers
Harada, R., Lerdsirisuk, P., Shimizu, Y., Yokoyama, Y., Du, Y., Kudo, K., Ezura, M., Ishikawa, Y., Iwata, R., Shidahara, M., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.123.265593 · Cited by 20 · see citing works
The Role of Tau in Neuronal Function and Neurodegeneration
Aranda-Abreu, G. E., Rojas-Durán, F., Hernández‐Aguilar, M. E., Herrera‐Covarrubias, D., García, L. I., Toledo‐Cárdenas, M. R., & Chi-Castañeda, D. (2025) · Neurology International · doi:10.3390/neurolint17050075 · Cited by 18 · see citing works
Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET
Pawlik, D., Leuzy, A., Strandberg, O. T., & Smith, R. A. (2020) · NeuroImage · doi:10.1016/j.neuroimage.2020.117193 · Cited by 20 · see citing works
MRI-based Alzheimer’s disease-resemblance atrophy index in the detection of preclinical and prodromal Alzheimer’s disease
Liu, W., Initiative, A. D. N., Au, L. W. C., Abrigo, J., Luo, Y., Wong, A., Lam, B. Y. K., Fan, X., Kwan, P. W.-L., Ma, H. W., et al. (2021) · Aging · doi:10.18632/aging.203082 · Cited by 20 · see citing works
Integrating neuroinflammation biomarkers into the ATN(X) framework: Advances in Alzheimer's pathogenesis, diagnosis, and insights from non‐human primate models
Jin, Z., Lu, Y., Tang, H., & Cui, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70472 · Cited by 23 · see citing works
Primary age-related tauopathy
Richardson, T. E., Walker, J. M., Farrell, K. W., Oliveira, T. G., White, C. L., & Crary, J. F. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02943-x · Cited by 21 · see citing works
Towards cascading genetic risk in Alzheimer’s disease
Altmann, A., Aksman, L. M., Oxtoby, N. P., Young, A. L., ADNI, Weiner, M., Aisen, P., Petersen, R., Weiner, M., Aisen, P., et al. (2024) · Brain · doi:10.1093/brain/awae176 · Cited by 18 · see citing works
Self-citation
Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease
Buckley, R. F. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01026-5 · Cited by 18 · see citing works
Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers
Bisi, N., Pinzi, L., Rastelli, G., & Tonali, N. (2024) · Molecules · doi:10.3390/molecules29030722 · Cited by 13 · see citing works
Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter
Moscoso, A., Grothe, M. J., Schöll, M., & Initiative, A. D. N. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05195-5 · Cited by 16 · see citing works
Comparative assessment of regional tau distribution by Tau-PET and Post-mortem neuropathology in a representative set of Alzheimer’s & frontotemporal lobar degeneration patients
Gatto, R. G., Carlos, A., Reichard, R., Lowe, V., Whitwell, J., & Josephs, K. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284182 · Cited by 14 · see citing works
Self-citation
Quantification of Lewy body pathology by cerebrospinal fluid endpoint dilution RT-QuIC in a neuropathological autopsy cohort of clinically heterogeneous participants
Mastrangelo, A., Caldera, S., Mastenbroek, S. E., Vittoriosi, E., Janelidze, S., Serrano, G. E., Atri, A., Shill, H. A., Driver‐Dunckley, E. D., Mehta, S. H., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02904-4 · Cited by 15 · see citing works
Alzheimer's disease
Serrano‐Pozo, A., Escott‐Price, V., Grinberg, L. T., Pascoal, T. A., Suárez‐Calvet, M., Dubois, B., & Sperling, R. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00198-4 · Cited by 18 · see citing works
Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer’s Disease
Qiao, Z., Wang, G., Zhao, X. B., Wang, K., Fan, D., Chen, Q., & Ai, L. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.841942 · Cited by 15 · see citing works
Imaging tau pathology in Alzheimer’s disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies
Moscoso, A., Wren, M. C., Lashley, T., Årstad, E., Murray, M. E., Fox, N. C., Sander, K., & Schöll, M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00543-x · Cited by 16 · see citing works
Self-citation
Medial temporal tau predicts memory decline in cognitively unimpaired elderly
Kwan, A. T. H., Arfaie, S., Therriault, J., Azizi, Z., Lussier, F. Z., Tissot, C., Chamoun, M., Bezgin, G., Servaes, S., Stevenon, J., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac325 · Cited by 15 · see citing works

[18F]Flortaucipir PET to Autopsy Pathology Correlation in Alzheimer’s Disease and Other Neurodegenerative Diseases (2630)
Soleimani‐Meigooni, D. N., Iaccarino, L., Joie, R. L., Baker, S. L., Bourakova, V., Boxer, A. L., Edwards, L., Eser, R. A., Gorno‐Tempini, M. L., Jagust, W. J., et al. (2020) · Neurology · doi:10.1212/wnl.94.15_supplement.2630
O4‐12‐01: TAU PET IMAGING CORRELATES WITH NEUROPATHOLOGY
Lowe, V. J., Lundt, E. S., Albertson, S. M., Nancy, S., Min, H.-K. P., Fang, P., Senjem, M. L., Schwarz, C. G., Parisi, J. E., Kantarci, K., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.4806
Self-citation
Correlation between in vivo 18 F‐flortaucipir PET and whole‐brain postmortem histological tau signals in Alzheimer's disease
Chao, Y., Chen, Y., Chadwick, T. A., Harrison, T. M., Iaccarino, L., Heinsen, H., Ushizima, D. M., Tosun, D., Jagust, W. J., & Grinberg, L. T. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71453
[18F]Flortaucipir PET to autopsy pathology comparisons in Alzheimer’s disease and other neurodegenerative diseases
Soleimani‐Meigooni, D. N., Iaccarino, L., Joie, R. L., Baker, S. L., Bourakova, V., Boxer, A. L., Edwards, L., Eser, R. A., Tempini, M. L. G., Jagust, W. J., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.046262 · Cited by 1 · see citing works
P2‐439: [18F]FLORTAUCIPIR PET AND PATHOLOGY CORRELATIONS IN ALZHEIMER'S DISEASE, NON‐ALZHEIMER'S TAUOPATHIES, AND OTHER NEURODEGENERATIVE DISEASES
Soleimani‐Meigooni, D. N., Iaccarino, L., Joie, R. L., Lesman‐Segev, O. H., Bourakova, V., Strom, A., Edwards, L., Baker, S. L., Janabi, M., Eser, R. A., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.2846

Authors: Lowe, V. J., Lundt, E. S., Albertson, S. M., Min, H., Fang, P., Przybelski, S. A., Senjem, M. L., Schwarz, C. G., Kantarci, K., Boeve, B., Jones, D. T., Reichard, R. R., Tranovich, J. F., Hanna Al‐Shaikh, F. S., Knopman, D. S., Jack, C. R., Dickson, D. W., Petersen, R. C., & Murray, M. E.
Affiliations: Mayo Clinic (US)
Department of Neuroscience Mayo Clinic Jacksonville FL USA
Corresponding author: Lowe, Val J.
Murray, Melissa E.
ORCID: Lowe, Val J.
Lundt, Emily S.
Min, Hoon‐Ki
Fang, Ping
Przybelski, Scott A.
Senjem, Matthew L.
Schwarz, Christopher G.
Kantarci, Kejal
Boeve, Bradley
Jones, David T.
Reichard, R. Ross
Knopman, David S.
Jack, Clifford R.
Dickson, Dennis W.
Petersen, Ronald C.
Murray, Melissa E.
Venue: Alzheimer's & Dementia
Publisher: Wiley
Published: 2020-01-04
Volume: 16
Issue: 3
Pages: 561-571
ISSN: 1552-5260 (ISSN-L)
1552-5279
DOI: 10.1016/j.jalz.2019.09.079
PMC: PMC7067654
OpenAlex: W2991594523
Cited by: 203
References: 44
Citations by year: 2026: 26 · 2025: 37 · 2024: 28 · 2023: 30 · 2022: 33 · 2021: 30 · 2020: 18
FWCI: 15.87
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Alzheimer s & Dementia (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (P50 AG016574, R01 NS89757, R01 NS089544, R01 DC10367, R01 AG011378, R01 AG041851, R01 AG034676, R01 AG054449, R01 NS097495, U01 AG006786, R21 NS094489)
Robert Wood Johnson Foundation
Mayo Foundation for Medical Education and Research
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords: tau PET, flortaucipir
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Autopsy, Brain, Female, Humans, Male, tau Proteins, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tau-positron emission tomography correlates with neuropathology findings.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks